Study: Targeting specific genomic mutation in breast cancer improves survival

Related video Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018. “Alpelisib is the first drug to show a benefit in a genomic subgroup of breast cancer patients,” […]

Health Highlights: Oct. 22, 2018

Related video All News Consumer Pro New Drugs Pipeline Clinical Trials FDA Alerts More Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Immunotherapy-Chemo Combo Extends Lives of Women With Aggressive Breast Cancer Treatment with immunotherapy plus chemotherapy extended the lives of women with an aggressive form […]

Targeted drug and hormone therapy combination extends breast cancer survival

Related video Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found. Women taking palbociclib together with hormone therapy lived seven months longer than those on hormone treatment alone – adding to previous data showing the combination could delay the disease’s progression. The […]

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Related video Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach. Restoring patients’ immune response against cancer cells with […]